Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat and Carfilzomib in Relapsed/Refractory Multiple Myeloma
NCT01496118Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2011
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Dec 2011; status: completed.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01496118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496118.